This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACLX

Arcellx (ACLX) Stock Price, News & Analysis

Arcellx logo

About Arcellx Stock (NASDAQ:ACLX)

Key Stats

Today's Range
$114.99
▼
$115.13
50-Day Range
$113.76
▼
$115.10
52-Week Range
$47.86
▼
$115.13
Volume
14.67 million shs
Average Volume
1.50 million shs
Market Capitalization
$6.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.08
Consensus Rating
Hold

Company Overview

Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region.

Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.

AI Generated. May Contain Errors.

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACLX Stock News Headlines

Gilead extends Arcellx tender offer again
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Arcellx Inc.
See More Headlines

ACLX Stock Analysis - Frequently Asked Questions

Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings data on Thursday, February, 26th. The company reported ($1.01) earnings per share for the quarter, meeting the consensus estimate of ($1.01). The company had revenue of $1.65 million for the quarter, compared to the consensus estimate of $13.40 million. Arcellx had a negative trailing twelve-month return on equity of 55.42% and a negative net margin of 1,027.26%.

Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Block (XYZ), PayPal (PYPL), Oklo (OKLO) and Broadcom (AVGO).

Company Calendar

Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACLX
CIK
1786205
Fax
N/A
Employees
80
Year Founded
2015

Price Target and Rating

High Price Target
$120.00
Low Price Target
$82.00
Potential Upside/Downside
-2.6%
Consensus Rating
Hold
Rating Score (0-4)
2.06
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$228.93 million
Net Margins
-1,027.26%
Pretax Margin
-1,026.94%
Return on Equity
-55.42%
Return on Assets
-36.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.44
Quick Ratio
4.44

Sales & Book Value

Annual Sales
$22.29 million
Price / Sales
301.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.96 per share
Price / Book
16.53

Miscellaneous

Outstanding Shares
58,480,000
Free Float
53,597,000
Market Cap
$6.73 billion
Optionable
Optionable
Beta
0.25

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:ACLX) was last updated on 4/28/2026 by MarketBeat.com Staff.
From Our Partners